Rohto Pharmaceutical Co.,Ltd.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Rohto Pharmaceutical Co.,Ltd. owes ¥0.33 for every ¥1 it owns. Net profit rose 11% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Compared with Consumer Defensive companies in Japan · latest annual results Mar 2026.
P/E ratio
19.7Investors pay ¥19.7 for every ¥1 of Rohto Pharmaceutical Co.,Ltd.'s yearly profit, higher than 64% of Consumer Defensive companies in Japan.
P/B ratio
1.98The share price is 1.98 times Rohto Pharmaceutical Co.,Ltd.'s book value per share, higher than 78% of Consumer Defensive companies in Japan.
Market cap
¥613.5 BThe total market value of all of Rohto Pharmaceutical Co.,Ltd.'s shares at today's price (share price × number of shares), larger than 93% of Consumer Defensive companies in Japan. PosiCap size class: Meso Cap.
Net worth (book value)
¥309.5 BWhat Rohto Pharmaceutical Co.,Ltd. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥1,376Net worth divided by the number of shares. The share price of ¥2,727 is 2.0 times this, which is the P/B above.
Return on equity (ROE)
10.9%Rohto Pharmaceutical Co.,Ltd. earned 10.9% on its shareholders' money over the last year, higher than 70% of Consumer Defensive companies in Japan.
Owes vs Owns
0.33×Rohto Pharmaceutical Co.,Ltd. owes ¥0.33 for every ¥1 it owns (low).
Dividend yield
1.80%Rohto Pharmaceutical Co.,Ltd. pays 1.80% of its share price as dividends a year, lower than 67% of dividend-paying Consumer Defensive companies in Japan.
Revenue growth
+11%Revenue rose 11% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Profit growth
+11%Net profit rose 11% in the year to Mar 2026, and grew 9% a year on average over 3 years.
Profit margin
10.0%Rohto Pharmaceutical Co.,Ltd. keeps ¥10 of every ¥100 of revenue as net profit.
Cash quality
1.4×Cash from Rohto Pharmaceutical Co.,Ltd.'s business was 1.4× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
32.0×Rohto Pharmaceutical Co.,Ltd.'s operating profit covered its interest costs 32.0 times in the year to Mar 2026.
Cash vs debt
Net cashRohto Pharmaceutical Co.,Ltd. held ¥26.6 B more cash than debt (net cash) at Mar 2026.
Questions
What is Rohto Pharmaceutical Co.,Ltd.'s P/E ratio?
Investors pay ¥19.7 for every ¥1 of Rohto Pharmaceutical Co.,Ltd.'s yearly profit, higher than 64% of Consumer Defensive companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rohto Pharmaceutical Co.,Ltd.: ¥613.5 B ÷ ¥309.5 B (30 Jun 2026) = 2.0.
What is Rohto Pharmaceutical Co.,Ltd.'s return on equity?
Rohto Pharmaceutical Co.,Ltd. earned 10.9% on its shareholders' money over the last year, higher than 70% of Consumer Defensive companies in Japan.
How much does Rohto Pharmaceutical Co.,Ltd. owe compared with what it owns?
Rohto Pharmaceutical Co.,Ltd. owes ¥0.33 for every ¥1 it owns (low).
Does Rohto Pharmaceutical Co.,Ltd. pay a dividend?
Yes. Rohto Pharmaceutical Co.,Ltd. pays 1.80% of its share price as dividends a year, lower than 67% of dividend-paying Consumer Defensive companies in Japan.
Is Rohto Pharmaceutical Co.,Ltd.'s revenue growing?
Revenue rose 11% in the year to Mar 2026, and grew 13% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.